TMP-SMX is commonly used for Pneumocystis jirovecii pneumonia prophylaxis.

• A. It is commonly used for Pneumocystis jirovecii pneumonia prophylaxis.
• B. It is primarily used for regional anaerobic infections.
• C. It is not effective against Pneumocystis jirovecii pneumonia.
• D. It is primarily an antifungal agent.

Answer: (A)

TMP-SMX is the go-to prophylaxis for Pneumocystis jirovecii pneumonia because it reliably prevents infection in people at high risk and is practical for long-term use. It’s a synergistic combination that blocks two steps in folate synthesis, giving potent activity against Pneumocystis and making it effective for both preventing and treating PJP. This is why it’s routinely used in at-risk groups such as people with advanced HIV, organ transplant recipients, or patients on heavy immunosuppression. The other statements don’t fit: it isn’t primarily used for regional anaerobic infections, it is effective against PJP (so saying it isn’t would be incorrect), and it isn’t primarily an antifungal agent—it's an antibiotic/antiparasitic approach that targets folate synthesis.